Women's Health Policy

ABORTION IN THE U.S.

CONTRACEPTIve care IN THE U.S.

New and noteworthy

Over-the-Counter Oral Contraceptive Pills

In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

811 - 820 of 869 Results

  • Abortion Bans May Limit Essential Medications for Women with Chronic Conditions

    Issue Brief

    This analysis uses the 2019 IBM MarketScan claims data to look at prescriptions of methotrexate and misoprostol, two drugs that can be used to terminate pregnancies, but are also used to manage chronic conditions like cancer, autoimmune diseases, and abnormal bleeding. These drugs may be restricted in response to state abortion bans, which we find will disproportionately affect women of reproductive age who make up the majority of those who rely on these drugs.

  • Analysis Reveals How Abortion Boosted Democratic Candidates in Tuesday’s Midterm Election

    News Release

    While inflation was clearly at the top of voters’ minds in this year’s midterm elections, the Supreme Court decision overturning Roe v. Wade played a significant role in motivating key voting blocs that likely contributed to the Democratic party’s stronger-than-expected performance, a new analysis of KFF’s supplemental questions on the Associated Press VoteCast survey of midterm voters. About four in ten (38%) voters overall said that the Supreme Court decision ending the constitutional right to an abortion had a…

  • Fewer than Half of Employed Women Say Their Employer Offers a Paid Parental Leave or Family and Medical Leave Benefit

    News Release

    A new KFF analysis finds that fewer than half of employed women ages 18-64 say their employer offers a paid parental leave benefit, such as maternity or paternity leave (43%) or family and medical leave (44%). Access to these workplace benefits varies widely by employment status, income, location, and level of education. Women who work full-time and have higher incomes are more likely than their part-time or low-income counterparts to say their employer offers any…

  • Medication Abortion in the Courts: What’s at Stake?

    News Release

    Access to medication abortion has emerged as a central issue following the Dobbs decision overturning Roe v. Wade. There is ongoing litigation in four federal cases about the FDA’s approval and regulation of mifepristone, one of the two drugs used in medication abortion. Mifepristone, approved by the FDA in 2000, has a long record of safety and effectiveness and has been used by more than 5 million people in the United States. In the most…

  • Legal Challenges to the FDA Approval of Medication Abortion Pills

    Issue Brief

    This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA's approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.

  • Will Insurance Cover Over-the-Counter Contraceptive Pills? A Discussion of Coverage Options and Challenges

    Event Date:
    Event

    The U.S. Food and Drug Administration recently approved Opill—the first over-the-counter daily oral contraceptive pill in the United States. Beginning in early 2024, people will be able to purchase Opill without a prescription, expanding options for contraceptive access across the country. On September 15, 2023, a panel of experts joined Laurie Sobel, associate director for KFF’s Women’s Health Policy program, to explore approaches to covering over-the-counter oral contraception without a prescription. The panel discussed lessons…

  • KFF Examines Challenges in Navigating Coverage for Opill, the First Over-the-Counter Daily Oral Contraceptive Pill, Coming to Market Next Year 

    News Release

    As Opill—the first over-the-counter daily oral contraceptive pill in the United States—is expected to be available for purchase in early 2024, new research conducted by KFF examines barriers to its accessibility for consumers and challenges in providing insurance coverage for it. Based on interviews with nearly 80 representatives from private insurance plans, state Medicaid programs, chain pharmacies, and other key groups, the report provides a deeper view into the operational challenges in expanding access to…